{
  "eval_id": "S26",
  "eval_file": "evals/single/S26.json",
  "timestamp": "2025-09-18T16:40:35.635814Z",
  "model": "gpt-4.1",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who have received endocrine therapy and at least two prior systemic therapies, including a CDK4/6 inhibitor. The main on-label points are its use after these prior lines and its established benefit in this setting per the EMA-approved SmPC. Please send the SmPC by email if you want to highlight a specific figure."
}